{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:10:19Z","timestamp":1719972619042},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00520-017-3732-6","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T04:44:41Z","timestamp":1493354681000},"page":"3217-3224","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment"],"prefix":"10.1007","volume":"25","author":[{"given":"Aleksandra P.","family":"Vidisheva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob D","family":"Bitran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad A.","family":"Tabbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Z.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura V.","family":"Stampleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald G.","family":"Steis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi M.","family":"Moezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina A.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina M","family":"Maluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle A","family":"Udd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrooz","family":"Eshaghian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youram","family":"Nassir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"3732_CR1","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071\u20133076","journal-title":"Cancer Res"},{"key":"3732_CR2","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ (2005) Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65:11510\u201311519","journal-title":"Cancer Res"},{"key":"3732_CR3","first-page":"3297","volume":"95","author":"L Shao","year":"2015","unstructured":"Shao L, Wang S, Meng H, Qian W, Mai W, Yu W, Tong H, Mao L, Wei J, Qian J, Jin J (2015) Bortezomib-induced peripheral neuropathy in multiple myeloma patients. Zhonghua Yi Xue Za Zhi 95:3297","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"3732_CR4","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine D, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"3732_CR5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine D, Schenkein DP, Anderson KC (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172","journal-title":"Br J Haematol"},{"key":"3732_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","volume":"13","author":"AJ Windebank","year":"2008","unstructured":"Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27\u201346","journal-title":"J Peripher Nerv Syst"},{"key":"3732_CR7","first-page":"6316","volume":"9","author":"PM Voorhees","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316\u20136325","journal-title":"Clin Cancer Res"},{"key":"3732_CR8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ctrv.2005.10.001","volume":"31","author":"G Jackson","year":"2005","unstructured":"Jackson G, Einsele H, Moreau P, Miguel JS (2005) Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 31:591\u2013602","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3732_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/ehm.12.26","volume":"5","author":"RZ Khan","year":"2012","unstructured":"Khan RZ, Badros A (2012) Role of carfilzomib in the treatment of multiple myeloma. Expert Rev Hematol 5(4):361\u2013372","journal-title":"Expert Rev Hematol"},{"key":"3732_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","volume":"33","author":"M Morawska","year":"2015","unstructured":"Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M (2015) Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 33:113\u2013119","journal-title":"Hematol Oncol"},{"key":"3732_CR11","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113\u20133120","journal-title":"J Clin Oncol"},{"key":"3732_CR12","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","volume":"110","author":"A Badros","year":"2007","unstructured":"Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042\u20131049","journal-title":"Cancer"},{"key":"3732_CR13","first-page":"309","volume":"83","author":"S Bang","year":"2006","unstructured":"Bang S, Lee JH, Yoon S, Park S, Min C, Kim C, Suh C, Sohn SK, Min Y, Lee J, Kim K, Seong C, Yoon H, Cho KS, Jo D, Lee KH, Lee N, Kim CS (2006) Korean multiple myeloma working party 2006. A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma International Journal of Hematology 83:309\u2013313","journal-title":"A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma International Journal of Hematology"},{"key":"3732_CR14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","volume":"84","author":"R Sood","year":"2009","unstructured":"Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ (2009) Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 84:657\u2013660","journal-title":"Am J Hematol"},{"key":"3732_CR15","first-page":"755","volume":"6","author":"J Wolf","year":"2008","unstructured":"Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS (2008) Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clinical advances in hematology & oncology: H&O 6:755\u2013760","journal-title":"Clinical advances in hematology & oncology: H&O"},{"key":"3732_CR16","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/cncr.21427","volume":"104","author":"JR Berenson","year":"2005","unstructured":"Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K (2005) Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104:2141\u20132148","journal-title":"Cancer"},{"key":"3732_CR17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clml.2014.03.005","volume":"14","author":"KB Knopf","year":"2014","unstructured":"Knopf KB, Duh MS, Lafeuille M, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL (2014) Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clinical lymphoma, myeloma & leukemia 14:380\u2013388","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"key":"3732_CR18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"3732_CR19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","volume":"92","author":"S Ciolli","year":"2007","unstructured":"Ciolli S, Leoni F, Casini C, Bosi A (2007) Feasibility and efficacy of bortezomib retreatment in multiple myeloma. Haematologica 92:95 Abstract 0260","journal-title":"Haematologica"},{"key":"3732_CR20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3816\/CLM.2008.n.016","volume":"8","author":"TM Conner","year":"2008","unstructured":"Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA (2008) An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 8:140\u2013145","journal-title":"Clin Lymphoma Myeloma"},{"key":"3732_CR21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","volume":"160","author":"MT Petrucci","year":"2013","unstructured":"Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Blad\u00e9 J (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160:649\u2013659","journal-title":"Br J Haematol"},{"key":"3732_CR22","first-page":"405","volume":"20","author":"A Oriol","year":"2015","unstructured":"Oriol A, Giraldo P, Kotsianidis I, Couturier C, Olie R, Angermund R, Corso A (2015) Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study. Hematology (Amsterdam, Netherlands) 20:405\u2013409","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"3732_CR23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3816\/CLM.2008.n.017","volume":"8","author":"J El-Cheikh","year":"2008","unstructured":"El-Cheikh J, Stoppa A, Bouabdallah R, de Lavallade H, Coso D, de Collela JS, Auran-Schleinitz T, Gastaut J, Blaise D, Mohty M (2008) Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma 8:146\u2013152","journal-title":"Clin Lymphoma Myeloma"},{"key":"3732_CR24","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","volume":"125","author":"AK Nooka","year":"2015","unstructured":"Nooka AK, Kastritis E, Dimopoulos MA, Lonial S (2015) Treatment options for relapsed and refractory multiple myeloma. Blood 125:3085\u20133099","journal-title":"Blood"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3732-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T00:05:29Z","timestamp":1504051529000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3732-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3732"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3732-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}